EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?

Runan Sheng, Qiong Wu, Kejia Lan

Gland Surgery · 2026-07 · 15 (7) · 203-203

DOI: 10.21037/gs-2026-0177 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Gland Surgery, 2026-07. Verfasst von Runan Sheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Qinghai University, Xining, China. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

FOLFIRINOXPancreatic ductal adenocarcinoma (PDAC)borderline resectablemolecular biomarkersneoadjuvant therapy

Autor:innen und Institutionen

  • School of Pharmacy, Qinghai University, Xining, China.
  • Department of Pathophysiology, Qinghai University Medical College, Xining, China.
  • Department of Hepatobiliary Diseases, Qinghai Tibetan Hospital, Xining, China.

Zitieren

APA

Sheng, R., Wu, Q., & Lan, K. (2026). Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?. Gland Surgery, 15(7), 203-203. https://doi.org/10.21037/gs-2026-0177

Vancouver

Sheng R, Wu Q, Lan K. Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?. Gland Surgery. 2026;15(7):203-203. doi:10.21037/gs-2026-0177

BibTeX
@article{Sheng2026,
  author = {Sheng, Runan and Wu, Qiong and Lan, Kejia},
  title = {Perioperative pancreatic ductal adenocarcinoma care in 2025: who needs neoadjuvant?—who needs radiation?},
  journal = {Gland Surgery},
  year = {2026},
  volume = {15},
  number = {7},
  pages = {203--203},
  doi = {10.21037/gs-2026-0177}
}
Kostenlos starten →